Clinical Trials
2
0 active
Approvals
4
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
Recruiting
2
100.0%
- BAMF Health is conducting clinical trials for a new theranostic treatment targeting colorectal cancer, the second-leading cause of cancer deaths in the United States with over 55,000 expected deaths this year. - The personalized targeted radiation medicine uses imaging agents to identify cancer-specific proteins and then delivers therapeutic agents to the same locations with high precision and minimal side effects. - The ongoing trials are showing progress, with the next steps involving continued target identification and eventual FDA approval for this precision treatment approach.
- The University of Kansas Health System, University of Kansas Medical Center, Children's Mercy, and BAMF Health announced plans to establish one of the nation's first fully integrated theranostics platforms serving both adult and pediatric patients. - The collaboration will create a state-of-the-art facility housing radiopharmaceutical production, molecular imaging, radiopharmaceutical therapy, and radioligand clinical trials in one location. - Children's Mercy represents one of the first pediatric health systems to invest early in theranostics technology, ensuring children access to this precision medicine approach. - The platform will expand beyond current applications in metastatic prostate cancer and neuroendocrine cancer to include clinical trials for neurologic conditions such as Alzheimer's disease.
- BAMF Health and Henry Ford Health announced a strategic partnership to establish a Comprehensive Theranostics Center in downtown Detroit, expanding patient access to precision medicine and molecular imaging. - The 45,000-square-foot facility will house molecular imaging and therapy clinics along with a commercial radiopharmacy, representing BAMF Health's second comprehensive center after their Grand Rapids flagship. - The partnership combines BAMF Health's global theranostics leadership with Henry Ford Health's century-long clinical excellence to deliver cutting-edge radiopharmaceutical therapy and research capabilities. - The center will serve as anchor tenants in the Life Sciences Building, driving economic growth and positioning Michigan as a national leader in healthcare innovation.
- Archeus Technologies has dosed the first patient in a Phase 1 clinical trial of ART-101, a novel PSMA-targeting radioligand therapy for metastatic castration-resistant prostate cancer. - Preclinical studies demonstrated that ART-101 exhibits higher tumor uptake and retention while showing lower normal tissue and salivary gland uptake compared to current FDA-approved PSMA-targeting agents. - The Phase 1 study will enroll approximately 10 mCRPC patients to evaluate safety, biodistribution, and tumor targeting using SPECT/CT imaging with [111In]In-ART-101. - The therapy was developed at the University of Wisconsin-Madison and aims to address key limitations of existing radiopharmaceutical therapies, particularly reducing side effects like xerostomia.
- ITM Isotope Technologies Munich will present post hoc subgroup analyses from its successful Phase 3 COMPETE trial at the 2025 NANETS symposium in Austin, Texas. - The COMPETE trial demonstrated that 177Lu-edotreotide achieved clinically and statistically significant improvement in progression-free survival compared to everolimus in patients with Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors. - The company will also host a satellite symposium focusing on therapy sequencing strategies for GEP-NETs, featuring leading oncologists from major cancer centers. - ITM's radiopharmaceutical approach represents a new generation of targeted treatments for hard-to-treat tumors, with multiple Phase 3 studies advancing their precision oncology pipeline.
- PSMA PET imaging has revolutionized prostate cancer detection and management, particularly in biochemical recurrence settings, with multiple FDA-approved agents now available including gallium-68 PSMA-11, piflufolastat F 18, and flotufolastat F 18. - The newer agent flotufolastat F 18 offers unique advantages in postprostatectomy recurrence scenarios due to its reduced bladder activity, allowing better visualization of potential recurrence in the prostate bed. - While PSMA PET has largely replaced fluciclovine F 18, the metabolic tracer still maintains a role in specific scenarios including tumors with low PSMA expression and neuroendocrine differentiation cases. - Expert panels emphasize that agent selection often depends on institutional availability and specific clinical contexts, as detection rates and sensitivity remain comparable between different PSMA PET tracers.
